1-3 of 3
Yonghan He, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

DT2216, a BCL-XL Proteolysis Targeting Chimera (PROTAC), Is a Potent Anti T-Cell Lymphoma Agent That Does Not Induce Significant Thrombocytopenia

Yonghan He, MD, Raphael Koch, Vivekananda Budamagunta, Dongwen Lv, Sajid Khan, Xuan Zhang, Janet S Wiegand, Guangrong Zheng, David M. Weinstock, MD, Daohong Zhou
Journal: Blood
Blood (2019) 134 (Supplement_1): 303.
https://doi.org/10.1182/blood-2019-125820
Published: 2019
Journal Articles

Long-Term Clearance of Senescent Cells Prevents the Hematopoietic Stem Cell Aging in Naturally Aged Mice

Yonghan He, MD, Jianhui Chang, Dongwen Lv, Ha-neui Kim, Maria Almeida, Xin Zhang, Xinjian Mao, PhD, Xinghui Zhao, PhD, Linheng Li, PhD, Judith Campisi, Ying Liang, MD PhD, Daohong Zhou
Journal: Blood
Blood (2019) 134 (Supplement_1): 1204.
https://doi.org/10.1182/blood-2019-123159
Published: 2019
Journal Articles

DT2216, a Synthetic Proteolytic Selectively Targeting Bcl-X L for Ubiquitination and Degradation in Tumor Cells but Not in Platelets, Is a Safer and More Potent Antitumor Agent Than Navitoclax

Sajid Khan, PhD, Xuan Zhang, BMBS, Dongwen Lv, PhD, Yonghan He, MD, Peiyi Zhang, MS, Xingui Liu, PhD, Dinesh Thummuri, PhD, Qi Zhang, PhD, Marina Y. Konopleva, MD PhD, Robert A. Hromas, MD, Guangrong Zheng, Daohong Zhou, MD
Journal: Blood
Blood (2018) 132 (Supplement 1): 2698.
https://doi.org/10.1182/blood-2018-99-114762
Published: 2018